{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:14:50Z","timestamp":1789722890684,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1124\/dmd.105.004796","type":"journal-article","created":{"date-parts":[[2005,6,25]],"date-time":"2005-06-25T00:33:43Z","timestamp":1119659623000},"page":"1361-1366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS"],"prefix":"10.1016","volume":"33","author":[{"given":"Miyuki","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kiyotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Saruwatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kamataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.004796_bib1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1006\/bbrc.2001.4524","article-title":"A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation.","volume":"281","author":"Ariyoshi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.105.004796_bib2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1006\/bbrc.2001.4422","article-title":"A novel single nucleotide polymorphism altering stability and activity of CYP2A6.","volume":"281","author":"Ariyoshi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.105.004796_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00008571-200011000-00003","article-title":"Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.","volume":"10","author":"Ariyoshi","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00008571-199206000-00003","article-title":"Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.","volume":"2","author":"Butler","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/clpt.1987.126","article-title":"A urinary metabolite ratio that reflects systemic caffeine clearance.","volume":"42","author":"Campbell","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/clpt.1994.30","article-title":"Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways.","volume":"55","author":"Carrillo","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00008571-200206000-00005","article-title":"A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur.","volume":"12","author":"Daigo","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0009-9236(96)80006-3","article-title":"Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.","volume":"59","author":"Denaro","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/abbi.1997.9964","article-title":"Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.","volume":"341","author":"Draper","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.105.004796_bib10","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/carcin\/bgh258","article-title":"Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.","volume":"25","author":"Fujieda","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.105.004796_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/clpt.1983.80","article-title":"Variability in caffeine metabolism.","volume":"33","author":"Grant","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","article-title":"Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.","volume":"2","author":"Gu","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0090-9556(25)08231-5","article-title":"In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.","volume":"13","author":"Inaba","year":"1985","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.004796_bib14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s002040050005","article-title":"CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.","volume":"73","author":"Inoue","year":"2000","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.105.004796_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0006-2952(97)00643-6","article-title":"High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli.","volume":"55","author":"Iwata","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.105.004796_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.1991.8","article-title":"Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.","volume":"49","author":"Kalow","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/clpt.1993.63","article-title":"The use of caffeine for enzyme assays: a critical appraisal.","volume":"53","author":"Kalow","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00008571-200311000-00005","article-title":"Decreased coumarine 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).","volume":"13","author":"Kiyotani","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib19","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0090-9556(24)13674-4","article-title":"Roles of cytochromes P450 1A2, 2A6 and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.","volume":"28","author":"Komatsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.004796_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/bj2670365","article-title":"Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity.","volume":"267","author":"Miles","year":"1990","journal-title":"Biochem J"},{"key":"10.1124\/dmd.105.004796_bib21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0006-291X(02)00328-5","article-title":"CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.","volume":"293","author":"Nakamura","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.105.004796_bib22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0090-9556(25)08453-3","article-title":"Role of human cytochrome P4502A6 in C-oxidation of nicotine.","volume":"24","author":"Nakajima","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.004796_bib23","first-page":"377","article-title":"CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk.","volume":"11","author":"Nowell","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/dmd.105.004796_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-3565(24)38154-6","article-title":"A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans.","volume":"289","author":"Nunoya","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.004796_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/oxfordjournals.jbchem.a022464","article-title":"Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype.","volume":"126","author":"Nunoya","year":"1999","journal-title":"J Biochem (Tokyo)"},{"key":"10.1124\/dmd.105.004796_bib26","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/S0021-9258(20)82245-5","article-title":"The carbon monoxide-binding pigment of liver microsomes.","volume":"239","author":"Omura","year":"1964","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.105.004796_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpt19741519","article-title":"Effect of cigarette smoking on phenacetin metabolism.","volume":"15","author":"Pantuck","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0300-483X(99)00200-0","article-title":"CYP2A6: a human coumarin 7-hydroxylase.","volume":"144","author":"Pelkonen","year":"2000","journal-title":"Toxicology"},{"key":"10.1124\/dmd.105.004796_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.2001.4990","article-title":"Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.","volume":"284","author":"Pitarque","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.105.004796_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00008571-199210000-00005","article-title":"Interindividual variability of coumarin 7-hydroxylation in healthy volunteers.","volume":"2","author":"Rautio","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.2448875","article-title":"Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.","volume":"29","author":"Saiki","year":"1988","journal-title":"Science (Wash DC)"},{"key":"10.1124\/dmd.105.004796_bib32","series-title":"Molecular Cloning: A Laboratory Manual","author":"Sambrook","year":"1989"},{"key":"10.1124\/dmd.105.004796_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/abbi.1994.1099","article-title":"Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization and catalytic activities of the enzyme.","volume":"309","author":"Sandhu","year":"1994","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.105.004796_bib34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1067\/mcp.2002.126173","article-title":"A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test.","volume":"72","author":"Saruwatari","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.004796_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.004796_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00008571-200204000-00009","article-title":"Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.","volume":"12","author":"Ujjin","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.004796_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1006\/bbrc.2001.6209","article-title":"An in vivo pilot study characterizing the new CYP2A6*7, *8 and *10 alleles.","volume":"290","author":"Xu","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.105.004796_bib38","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bcp.2003.08.004","article-title":"Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.","volume":"66","author":"Yamaori","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.105.004796_bib39","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0090-9556(24)14927-6","article-title":"Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.","volume":"27","author":"Yamazaki","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.004796_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1365-2125.2002.01667.x","article-title":"Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.","volume":"54","author":"Yoshida","year":"2002","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624032689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624032689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.004796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:54:41Z","timestamp":1739901281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624032689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0090955624032689"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.004796","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.004796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}